

Gene Therapy Plus Specific Stop-Loss Rider

List of Covered Drugs

Current FDA-approved drugs covered under the rider:

Beqvez

Casgevy

Hemgenix

Kymriah—only for treatment of pediatric Acute Lymphoblastic Leukemia

Lenmeldy

Luxturna

Lyfgenia

Rethymic

Roctavian

Skysona

Zolgensma

Zynteglo

Medical Mutual is continually monitoring the gene therapy and specialty drug pipelines for future high-impact products that may be added to our Gene Therapy Plus coverage. Examples of conditions with potential upcoming gene therapies in the near-term include hemophilia, muscular dystrophy, AADC (Aromatic L-amino acid decarboxylase deficiency) as well as cellular therapies for various cancers.